Acetyl-Leucine Composition for Lysosomal Storage Disorder Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for lysosomal storage disorders (LSDs) are limited, with few curative treatments and most options only improving quality of life, and there is a need for improved treatments that can benefit all LSDs.
Innovation Solution
Acetyl-leucine or its pharmaceutically acceptable salts are used to treat LSDs by administering a therapeutically effective amount for durations ranging from at least 3 months to 5 years, which can delay or reverse the progression of symptoms and improve biochemical markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches (enzyme replacement therapy, bone marrow transplantation) are used, then quality of life is improved, but curative treatment is not achieved and disease progression continues
Solution Approach 1:
The patent converts the harmful accumulation of storage material in lysosomes into a beneficial effect by using acetyl-leucine to induce lysosomal exocytosis. This process actively eliminates the stored material that causes disease progression, transforming the pathological accumulation into a therapeutic opportunity for clearing lysosomal contents and reversing disease symptoms.
Solution Approach 2:
The patent changes the functional parameter of lysosomes from a static storage compartment to a dynamic exocytotic system. By administering acetyl-leucine, the lysosomal membrane permeability and exocytosis rate are modified, enabling the active expulsion of storage material. This parameter change transforms the lysosomal function to achieve therapeutic effect.
2Ease of operation
If enzyme replacement therapy is administered, then some symptoms are managed, but the treatment is not curative and requires continuous administration
Solution Approach 1:
The patent applies preliminary action by using acetyl-leucine to prime and activate lysosomal exocytosis pathways before significant damage occurs. By inducing exocytosis early in the disease course or at the onset of treatment, the therapy proactively clears storage material and prevents further accumulation, potentially achieving disease modification rather than just symptom management.
Solution Approach 2:
The patent enables the body's own lysosomal system to serve itself by activating endogenous exocytosis mechanisms. Instead of continuously administering external enzymes, acetyl-leucine triggers the cell's intrinsic ability to expel storage material through lysosomal exocytosis, allowing the system to self-regulate and potentially reducing the need for continuous external intervention.
3Productivity
If substrate reduction therapy using miglustat is used, then some benefit is reported, but the treatment is specific to certain LSDs and not generally applicable
Solution Approach 1:
The patent applies universality by developing a therapy that targets a common pathological mechanism (lysosomal storage) shared by multiple LSDs. Acetyl-leucine-induced lysosomal exocytosis is a general mechanism that can clear various types of storage material (lipids, proteins, carbohydrates) regardless of the specific enzyme deficiency, making the treatment broadly applicable across different LSD subtypes.
Solution Approach 2:
The patent uses acetyl-leucine as an intermediary substance that mediates the elimination of diverse storage materials. Rather than targeting specific enzymes or substrates, acetyl-leucine acts as a universal mediator that triggers lysosomal exocytosis, enabling the clearance of various storage products through a common pathway applicable to multiple LSDs.
Data Source
AI summary
The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.